Company intelligence / Profile preview
CKD BiO
Seoul, South Koreackdbio.com ↗
- Ownership
- Private
- Employees
- ~519
- Development stage
- Other
01
Overview
CKD BiO develops and manufactures high-value pharmaceutical ingredients—especially fermentation-based antibiotics, β-lactamase inhibitors, immunosuppressants—and next-generation probiotics. It has a robust R&D pipeline with clinical-stage assets in dermatology/aesthetics and oncology. The company also operates as a CMO/CDMO with global GMP-certified facilities.
- Therapeutic areas
- OncologyPsychiatryDermatology
- Modalities
- Small moleculeProtein drugBiological productAntibody-drug conjugatesiRNAProbiotics
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
Not specified in detail; company actively seeks global partners for pharmaceutical innovation. Likely collaborates with international pharma companies via its CMO/CDMO business.
Beyond the preview
Go deeper on CKD BiO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD BiO.